Non-alcoholic steatohepatitis in morbidly obese patients

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 1, 2013, Pages 17-29

  Tran, Albert ^a,b,c   Gual, Philippe ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE; CYTOKERATIN 18; CYTOKINE; IRON; TOLL LIKE RECEPTOR;

ADIPOSE TISSUE; CELL DEATH; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE MARKER; HUMAN; IMMUNOREGULATION; INFLAMMATION; INSULIN RESISTANCE; INTESTINE; LIVER CELL; LIVER INJURY; MORBID OBESITY; NATURAL KILLER T CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; REGULATORY MECHANISM; SHORT SURVEY; WHITE ADIPOSE TISSUE;

FATTY LIVER; HUMANS; OBESITY, MORBID;

EID: 84873121062     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.07.005     Document Type: Short Survey

References (153)

1. Gao B., Jeong W.I., Tian Z. Liver: an organ with predominant innate immunity. Hepatology 2008, 47:729-736.
2. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253.
3. Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40:S5-S10.
4. Younossi Z.M., Diehl A.M., Ong J.P. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002, 35:746-752.
5. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
6. Bacon B.R., Farahvash M.J., Janney C.G. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
7. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
8. Day C., James O. Steatohepatitis: a tale of two "hits" ?. Gastroenterology 1998, 114:842-845.
9. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin-resistance. Am J Med 1999, 107:450-455.
10. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin-resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
11. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
12. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114:147-152.
13. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343:1467-1476.
14. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin-resistance. J Clin Invest 2003, 112:1821-1830.
15. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
16. Winer S., Chan Y., Paltser G., Truong D., Tsui H., Bahrami J., et al. Normalization of obesity-associated insulin-resistance through immunotherapy. Nat Med 2009, 15:921-929.
17. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009, 15:914-920.
18. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009, 15:930-939.
19. Patsouris D., Li P.P., Thapar D., Chapman J., Olefsky J.M., Neels J.G. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 2008, 8:301-309.
20. Bertola A., Ciucci T., Rousseau D., Bourlier V., Duffaut C., Bonnafous S., et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes 2012, 61:2238-2247.
21. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-1812.
22. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. Jama 1999, 282:2131-2135.
23. Ford E.S. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999, 22:1971-1977.
24. Yudkin J.S., Stehouwer C.D., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin-resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999, 19:972-978.
25. Hak A.E., Stehouwer C.D., Bots M.L., Polderman K.H., Schalkwijk C.G., Westendorp I.C., et al. Associations of C-reactive protein with measures of obesity, insulin-resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999, 19:1986-1991.
26. Maachi M., Pieroni L., Bruckert E., Jardel C., Fellahi S., Hainque B., et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 2004, 28:993-997.
27. Frohlich M., Imhof A., Berg G., Hutchinson W.L., Pepys M.B., Boeing H., et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000, 23:1835-1839.
28. Aronson D., Bartha P., Zinder O., Kerner A., Markiewicz W., Avizohar O., et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004, 28:674-679.
29. Festa A., D'Agostino R.J., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin-resistance syndrome: the Insulin-resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
30. Pannacciulli N., Cantatore F.P., Minenna A., Bellacicco M., Giorgino R., De Pergola G. C-reactive protein is independently associated with total body fat, central fat, and insulin-resistance in adult women. Int J Obes Relat Metab Disord 2001, 25:1416-1420.
31. Haffner S.M., D'Agostino R.J., Festa A., Bergman R.N., Mykkanen L., Karter A., et al. Low insulin sensitivity (S(i)=0) in diabetic and nondiabetic subjects in the insulin-resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors?. Diabetes Care 2003, 26:2796-2803.
32. Sites C.K., Toth M.J., Cushman M., L'Hommedieu G.D., Tchernof A., Tracy R.P., et al. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 2002, 77:128-135.
33. Park S.H., Kim B.I., Yun J.W., Kim J.W., Park D.I., Cho Y.K., et al. Insulin-resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004, 19:694-698.
34. Koruk M., Taysi S., Savas M.C., Yilmaz O., Akcay F., Karakok M. Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol 2003, 14:12-17.
35. Yoneda M., Mawatari H., Fujita K., Iida H., Yonemitsu K., Kato S., et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007, 42:573-582.
36. Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol 2006, 45:879-881. 881-872; author reply.
37. Hui J.M., Farrell G.C., Kench J.G., George J. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology 2004, 39:1458-1459.
38. Anty R., Bekri S., Luciani N., Saint-Paul M.C., Dahman M., Iannelli A., et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome. Type 2 diabetes, and NASH. Am J Gastroenterol 2006, 101:1824-1833.
39. Zimmermann E., Anty R., Tordjman J., Verrijken A., Gual P., Tran A., et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol 2011, 55:660-665.
40. Ouchi N., Kihara S., Funahashi T., Nakamura T., Nishida M., Kumada M., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674.
41. Calabro P., Chang D.W., Willerson J.T., Yeh E.T. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005, 46:1112-1113.
42. Bertola A., Bonnafous S., Anty R., Patouraux S., Saint-Paul M.C., Iannelli A., et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One 2010, 5:e13577.
43. Linder S., Havelka A.M., Ueno T., Shoshan M.C. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004, 214:1-9.
44. Kramer G., Erdal H., Mertens H.J., Nap M., Mauermann J., Steiner G., et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004, 64:1751-1756.
45. Luft T., Conzelmann M., Benner A., Rieger M., Hess M., Strohhaecker U., et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 2007, 110:4535-4542.
46. Wieckowska A., Zein N.N., Yerian L.M., Lopez A.R., McCullough A.J., Feldstein A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
47. Feldstein A.E., Wieckowska A., Lopez A.R., Liu Y.C., Zein N.N., McCullough A.J. Cytokeratin-18 fragment levels as non-invasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078.
48. Diab D.L., Yerian L., Schauer P., Kashyap S.R., Lopez R., Hazen S.L., et al. Cytokeratin 18 fragment levels as a non-invasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008, 6:1249-1254.
49. Anty R., Iannelli A., Patouraux S., Bonnafous S., Lavallard V.J., Senni-Buratti M., et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010, 32:1315-1322.
50. Tamimi T.I., Elgouhari H.M., Alkhouri N., Yerian L.M., Berk M.P., Lopez R., et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011, 54:1224-1229.
51. Shen J., Chan H.L., Wong G.L., Choi P.C., Chan A.W., Chan H.Y., et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012, 56:1363-1370.
52. Joka D., Wahl K., Moeller S., Schlue J., Vaske B., Bahr M.J., et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012, 55:455-464.
53. Younossi Z.M., Jarrar M., Nugent C., Randhawa M., Afendy M., Stepanova M., et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008, 18:1430-1437.
54. Wong V.W., Wong G.L., Choi P.C., Chan A.W., Li M.K., Chan H.Y., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010, 59:969-974.
55. Gonzalez-Quintela A., Abdulkader I., Campos J., Fernandez-Hernandez L., Lojo S. Serum levels of keratin-18 fragments [tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. Dig Dis Sci 2009, 54:648-653.
56. Gonzalez-Quintela A., Garcia J., Campos J., Perez L.F., Alende M.R., Otero E., et al. Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19. Alcohol 2006, 38:45-49.
57. Li X., Zhang Y., Wu K., Fan D. Serum cytokeratin-18 fragment level: a non-invasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis. Hepatology 2010, 51:1865-1866.
58. Lavallard V.J., Bonnafous S., Patouraux S., Saint-Paul M.C., Rousseau D., Anty R., et al. Serum markers of hepatocyte death and apoptosis are non-invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One 2011, 6:e17599.
59. Valenti L., Ludovica Fracanzani A., Fargion S. The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?. Semin Immunopathol 2009, 31:359-369.
60. Albano E., Mottaran E., Vidali M., Reale E., Saksena S., Occhino G., et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005, 54:987-993.
61. Guebre-Xabier M., Yang S., Lin H.Z., Schwenk R., Krzych U., Diehl A.M. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 2000, 31:633-640.
62. Li Z., Lin H., Yang S., Diehl A.M. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002, 123:1304-1310.
63. Loffreda S., Yang S.Q., Lin H.Z., Karp C.L., Brengman M.L., Wang D.J., et al. Leptin regulates proinflammatory immune responses. Faseb J 1998, 12:57-65.
64. Li Z., Soloski M.J., Diehl A.M. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005, 42:880-885.
65. Elinav E., Pappo O., Sklair-Levy M., Margalit M., Shibolet O., Gomori M., et al. Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels. J Pathol 2006, 208:74-81.
66. Xu C.F., Yu C.H., Li Y.M., Xu L., Du J., Shen Z. Association of the frequency of peripheral natural killer T cells with nonalcoholic fatty liver disease. World J Gastroenterol 2007, 13:4504-4508.
67. Pacifico L., Di Renzo L., Anania C., Osborn J.F., Ippoliti F., Schiavo E., et al. Increased T-helper interferon-gamma-secreting cells in obese children. Eur J Endocrinol 2006, 154:691-697.
68. Syn W.K., Oo Y.H., Pereira T.A., Karaca G.F., Jung Y., Omenetti A., et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010, 51:1998-2007.
69. Cortez-Pinto H., de Moura M.C., Day C.P. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006, 44:197-208.
70. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
71. Wieckowska A., Papouchado B.G., Li Z., Lopez R., Zein N.N., Feldstein A.E. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008, 103:1372-1379.
72. Brunt E.M. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001, 21:3-16.
73. Bigorgne A.E., Bouchet-Delbos L., Naveau S., Dagher I., Prevot S., Durand-Gasselin I., et al. Obesity-induced lymphocyte hyperresponsiveness to chemokines: a new mechanism of Fatty liver inflammation in obese mice. Gastroenterology 2008, 134:1459-1469.
74. Joshi-Barve S., Barve S.S., Amancherla K., Gobejishvili L., Hill D., Cave M., et al. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 2007, 46:823-830.
75. Ito S., Yukawa T., Uetake S., Yamauchi M. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin Exp Res 2007, 31:S83-S87.
76. Bertola A., Deveaux V., Bonnafous S., Rousseau D., Anty R., Wakkach A., et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 2009, 58:125-133.
77. Diao H., Kon S., Iwabuchi K., Kimura C., Morimoto J., Ito D., et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004, 21:539-550.
78. Ashkar S., Weber G.F., Panoutsakopoulou V., Sanchirico M.E., Jansson M., Zawaideh S., et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000, 287:860-864.
79. Mimura S., Mochida S., Inao M., Matsui A., Nagoshi S., Yoshimoto T., et al. Massive liver necrosis after provocation of imbalance between Th1 and Th2 immune reactions in osteopontin transgenic mice. J Gastroenterol 2004, 39:867-872.
80. Lorena D., Darby I.A., Gadeau A.P., Leen L.L., Rittling S., Porto L.C., et al. Osteopontin expression in normal and fibrotic liver. altered liver healing in osteopontin-deficient mice. J Hepatol 2006, 44:383-390.
81. De Minicis S., Seki E., Uchinami H., Kluwe J., Zhang Y., Brenner D.A., et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 2007, 132:1937-1946.
82. Sahai A., Malladi P., Melin-Aldana H., Green R.M., Whitington P.F. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 2004, 287:G264-G273.
83. Syn W.K., Choi S.S., Liaskou E., Karaca G.F., Agboola K.M., Oo Y.H., et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011, 53:106-115.
84. Kawashima R., Mochida S., Matsui A., YouLuTu Z.Y., Ishikawa K., Toshima K., et al. Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 1999, 256:527-531.
85. Lee S.H., Seo G.S., Park Y.N., Yoo T.M., Sohn D.H. Effects and regulation of osteopontin in rat hepatic stellate cells. Biochem Pharmacol 2004, 68:2367-2378.
86. Lenga Y., Koh A., Perera A.S., McCulloch C.A., Sodek J., Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ Res 2008, 102:319-327.
87. Patouraux S., Bonnafous S., Voican C.S., Anty R., Saint-Paul M.C., Rosenthal-Allieri M.A., et al. The Osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One 2012, 7:e35612.
88. Suzuki K., Kumanogoh A., Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat Immunol 2008, 9:17-23.
89. Mizui M., Kumanogoh A., Kikutani H. Immune semaphorins: novel features of neural guidance molecules. J Clin Immunol 2009, 29:1-11.
90. Tilg H., Moschen A.R., Kaser A. Obesity and the microbiota. Gastroenterology 2009, 136:1476-1483.
91. Seki E., Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008, 48:322-335.
92. Poggi M., Bastelica D., Gual P., Iglesias M.A., Gremeaux T., Knauf C., et al. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin-resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007, 50:1267-1276.
93. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., et al. Metabolic endotoxemia initiates obesity and insulin-resistance. Diabetes 2007, 56:1761-1772.
94. Szabo G., Velayudham A., Romics L., Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res 2005, 29:140S-145S.
95. Rivera C.A., Adegboyega P., van Rooijen N., Tagalicud A., Allman M., Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007, 47:571-579.
96. Yang S.Q., Lin H.Z., Lane M.D., Clemens M., Diehl A.M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997, 94:2557-2562.
97. Li Z., Yang S., Lin H., Huang J., Watkins P.A., Moser A.B., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
98. Solga S.F., Diehl A.M. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003, 38:681-687.
99. Pendyala S., Walker J., Holt P.R. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 2012, 142:1100-1101e2.
100. Ting J.P., Willingham S.B., Bergstralh D.T. NLRs at the intersection of cell death and immunity. Nat Rev Immunol 2008, 8:372-379.
101. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
102. Sutterwala F.S., Ogura Y., Flavell R.A. The inflammasome in pathogen recognition and inflammation. J Leukoc Biol 2007, 82:259-264.
103. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
104. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
105. Csak T., Ganz M., Pespisa J., Kodys K., Dolganiuc A., Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011, 54:133-144.
106. George D.K., Goldwurm S., MacDonald G.A., Cowley L.L., Walker N.I., Ward P.J., et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998, 114:311-318.
107. MacDonald G.A., Bridle K.R., Ward P.J., Walker N.I., Houglum K., George D.K., et al. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J Gastroenterol Hepatol 2001, 16:599-606.
108. Xiong S., She H., Sung C.K., Tsukamoto H. Iron-dependent activation of NF-kappaB in Kupffer cells: a priming mechanism for alcoholic liver disease. Alcohol 2003, 30:107-113.
109. Bonkovsky H.L., Jawaid Q., Tortorelli K., LeClair P., Cobb J., Lambrecht R.W., et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999, 31:421-429.
110. Nelson J.E., Bhattacharya R., Lindor K.D., Chalasani N., Raaka S., Heathcote E.J., et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 2007, 46:723-729.
111. Younossi Z.M., Gramlich T., Bacon B.R., Matteoni C.A., Boparai N., O'Neill R., et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999, 30:847-850.
112. Valenti L., Fracanzani A.L., Bugianesi E., Dongiovanni P., Galmozzi E., Vanni E., et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010, 138:905-912.
113. Bekri S., Gual P., Anty R., Luciani N., Dahman M., Ramesh B., et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006, 131:788-796.
114. Luciani N., Brasse-Lagnel C., Poli M., Anty R., Lesueur C., Cormont M., et al. Hemojuvelin: a new link between obesity and iron homeostasis. Obesity (Silver Spring) 2011, 19:1545-1551.
115. Tussing-Humphreys L.M., Nemeth E., Fantuzzi G., Freels S., Guzman G., Holterman A.X., et al. Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity (Silver Spring) 2010, 18:1449-1456.
116. Anty R., Dahman M., Iannelli A., Gual P., Staccini-Myx A., Amor I.B., et al. Bariatric surgery can correct iron depletion in morbidly obese women: a link with chronic inflammation. Obes Surg 2008, 18:709-714.
117. Tussing-Humphreys L.M., Nemeth E., Fantuzzi G., Freels S., Holterman A.X., Galvani C., et al. Decreased serum hepcidin and improved functional iron status 6 months after restrictive bariatric surgery. Obesity (Silver Spring) 2010, 18:2010-2016.
118. Laine F., Jouannolle A.M., Morcet J., Brigand A., Pouchard M., Lafraise B., et al. Phenotypic expression in detected C282Y homozygous women depends on body mass index. J Hepatol 2005, 43:1055-1059.
119. Feldstein A.E., Gores G.J. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005, 10:3093-3099.
120. Malhi H., Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008, 134:1641-1654.
121. Feldstein A.E., Canbay A., Angulo P., Taniai M., Burgart L.J., Lindor K.D., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
122. Ribeiro P.S., Cortez-Pinto H., Sola S., Castro R.E., Ramalho R.M., Baptista A., et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004, 99:1708-1717.
123. Witek R.P., Stone W.C., Karaca F.G., Syn W.K., Pereira T.A., Agboola K.M., et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009, 50:1421-1430.
124. Mitchell C., Robin M.A., Mayeuf A., Mahrouf-Yorgov M., Mansouri A., Hamard M., et al. Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice. Am J Pathol 2009, 175:1929-1937.
125. Haedrich M., Dufour J.F. UDCA for NASH: end of the story?. J Hepatol 2011, 54:856-858.
126. Rodrigues C.M., Fan G., Ma X., Kren B.T., Steer C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998, 101:2790-2799.
127. Botla R., Spivey J.R., Aguilar H., Bronk S.F., Gores G.J. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995, 272:930-938.
128. Dufour J.F., Oneta C.M., Gonvers J.J., Bihl F., Cerny A., Cereda J.M., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006, 4:1537-1543.
129. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
130. Ratziu V., Sheikh M.Y., Sanyal A.J., Lim J.K., Conjeevaram H., Chalasani N., et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012, 55:419-428.
131. Ruhl C.E., Everhart J.E. Trunk fat is associated with increased serum levels of alanine aminotransferase in the United States. Gastroenterology 2010, 138:e1341-e1343. 1346-56.
132. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184.
133. Cancello R., Henegar C., Viguerie N., Taleb S., Poitou C., Rouault C., et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005, 54:2277-2286.
134. Aron-Wisnewsky J., Tordjman J., Poitou C., Darakhshan F., Hugol D., Basdevant A., et al. Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab 2009, 94:4619-4623.
135. Nagaya T., Tanaka N., Suzuki T., Sano K., Horiuchi A., Komatsu M., et al. Down-regulation of SREBP-1c is associated with the development of burned-out NASH. J Hepatol 2010, 53:724-731.
136. Petta S., Amato M.C., Di Marco V., Camma C., Pizzolanti G., Barcellona M.R., et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012, 35:238-247.
137. Cancello R., Tordjman J., Poitou C., Guilhem G., Bouillot J.L., Hugol D., et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006, 55:1554-1561.
138. Tordjman J., Divoux A., Prifti E., Poitou C., Pelloux V., Hugol D., et al. Structural and inflammatory heterogeneity in subcutaneous adipose tissue: relation with liver histopathology in morbid obesity. J Hepatol 2012, 56:1152-1158.
139. Nomiyama T., Perez-Tilve D., Ogawa D., Gizard F., Zhao Y., Heywood E.B., et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin-resistance in mice. J Clin Invest 2007, 117:2877-2888.
140. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin-resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116:1494-1505.
141. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006, 116:115-124.
142. Kamei N., Tobe K., Suzuki R., Ohsugi M., Watanabe T., Kubota N., et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin-resistance. J Biol Chem 2006, 281:26602-26614.
143. Kiefer F.W., Neschen S., Pfau B., Legerer B., Neuhofer A., Kahle M., et al. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia 2011, 54:2132-2142.
144. Zeyda M., Huber J., Prager G., Stulnig T.M. Inflammation correlates with markers of T-cell subsets including regulatory T cells in adipose tissue from obese patients. Obesity (Silver Spring) 2011, 19:743-748.
145. Nguyen M.T., Favelyukis S., Nguyen A.K., Reichart D., Scott P.A., Jenn A., et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007, 282:35279-35292.
146. Berndt B.E., Zhang M., Chen G.H., Huffnagle G.B., Kao J.Y. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J Immunol 2007, 179:6255-6262.
147. Wu H., Perrard X.D., Wang Q., Perrard J.L., Polsani V.R., Jones P.H., et al. CD11c expression in adipose tissue and blood and its role in diet-induced obesity. Arterioscler Thromb Vasc Biol 2010, 30:186-192.
148. Yekollu S.K., Thomas R., O'Sullivan B. Targeting curcusomes to inflammatory dendritic cells inhibits NF-kappaB and improves insulin-resistance in obese mice. Diabetes 2011, 60:2928-2938.
149. Mallat Z. The B-side story in insulin-resistance. Nat Med 2011, 17:539-540.
150. Winer D.A., Winer S., Shen L., Wadia P.P., Yantha J., Paltser G., et al. B cells promote insulin-resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 2011, 17:610-617.
151. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
152. Abdelmalek M.F., Suzuki A., Guy C., Unalp-Arida A., Colvin R., Johnson R.J., et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1961-1971.
153. Loguercio C., De Simone T., Federico A., Terracciano F., Tuccillo C., Di Chicco M., et al. Gut-liver axis: a new point of attack to treat chronic liver damage?. Am J Gastroenterol 2002, 97:2144-2146.